Rare DiseasesGene-silencing drug works in rare ALS that strikes young people
Ionis and Otsuka say ulefnersen improved survival and function in the phase 3 FUSION trial in FUS-ALS, an aggressive genetic motor neurone disease often seen in teenagers.
22 September 2026